ANNE TSAO to Imatinib Mesylate
This is a "connection" page, showing publications ANNE TSAO has written about Imatinib Mesylate.
Connection Strength
0.254
-
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201.
Score: 0.082
-
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
Score: 0.071
-
Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003 Dec 01; 98(11):2483-7.
Score: 0.041
-
STI-571 in chronic myelogenous leukaemia. Br J Haematol. 2002 Oct; 119(1):15-24.
Score: 0.038
-
Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2004 Jun 01; 100(11):2486-7; author reply 2487-8.
Score: 0.021